Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to ficerafusp alfa together with Keytruda (pembrolizumab) for the primary...
The U.S. Meals and Drug Administration (FDA) has accredited Inluriyo (imlunestrant) for the therapy of adults with estrogen receptor (ER)-positive and HER2-negative...
The U.S. Meals and Drug Administration lately accepted Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous use in adults and pediatric sufferers...
